[P02BB01, trichlorfon, Metrifonate may increase the bradycardic activities of Sotalol.]
[S02DA03, antipyrine, Antipyrine may decrease the antihypertensive activities of Sotalol.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Sotalol.]
[L04AA27, fingolimod, Sotalol may increase the bradycardic activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of hyperkalemia can be increased when Succinylcholine is combined with Sotalol.]
[J01EC02, sulfadiazine, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Sulfamethoxazole.]
[S01AB02, sulfisoxazole, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Sulfisoxazole.]
[M01AB02, sulindac, Sulindac may decrease the antihypertensive activities of Sotalol.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Sotalol.]
[A10BB04, glibornuride, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Glymidine.]
[M01AX04, apazone, Azapropazone may decrease the antihypertensive activities of Sotalol.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Sotalol is combined with Mercaptopurine.]
[N06DA01, tacrine, Tacrine may increase the bradycardic activities of Sotalol.]
[L02BA01, tamoxifen, The metabolism of Sotalol can be decreased when combined with Tamoxifen.]
[R03CC03, terbutaline, Sotalol may decrease the bronchodilatory activities of Terbutaline.]
[N07XX06, tetrabenazine, The metabolism of Sotalol can be decreased when combined with Tetrabenazine.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Sotalol.]
[A04AD10, dronabinol, The metabolism of Sotalol can be decreased when combined with Dronabinol.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Sotalol.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Sotalol is combined with Thalidomide.]
[R03DA07, theobromine, The risk or severity of adverse effects can be increased when Sotalol is combined with Theobromine.]
[R03DA04, theophylline, The metabolism of Sotalol can be decreased when combined with Theophylline.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Sotalol.]
[R06AD03, thiethylperazine, The serum concentration of Sotalol can be increased when it is combined with Thiethylperazine.]
[L01AC01, thiotepa, Thiotepa may increase the bradycardic activities of Sotalol.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Sotalol.]
[N05AB08, thioproperazine, The serum concentration of Sotalol can be increased when it is combined with Thioproperazine.]
[N05AC02, thioridazine, The metabolism of Sotalol can be decreased when combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Sotalol.]
[C01BB04, aprindine, Sotalol may increase the arrhythmogenic activities of Aprindine.]
[B02AB01, aprotinin, Aprotinin may increase the bradycardic activities of Sotalol.]
[B01AC05, ticlopidine, The metabolism of Sotalol can be decreased when combined with Ticlopidine.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Timolol is combined with Sotalol.]
[A10BB05, tolazamide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Tolazamide.]
[M02AX02, tolazoline, Sotalol may increase the orthostatic hypotensive activities of Tolazoline.]
[V04CA01, tolbutamide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Tolbutamide.]
[M02AA21, tolmetin, Tolmetin may decrease the antihypertensive activities of Sotalol.]
[N02AX02, tramadol, The metabolism of Sotalol can be decreased when combined with Tramadol.]
[N06AF04, tranylcypromine, The metabolism of Sotalol can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Sotalol.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Sotalol is combined with Tretinoin.]
[C03DB02, triamterene, The risk or severity of adverse effects can be increased when Triamterene is combined with Sotalol.]
[C03AA06, trichlormethiazide, Sotalol may increase the hypotensive activities of Trichlormethiazide.]
[S01EB04, demecarium, Demecarium may increase the bradycardic activities of Sotalol.]
[N05AB06, trifluoperazine, The serum concentration of Sotalol can be increased when it is combined with Trifluoperazine.]
[N05AA05, triflupromazine, The serum concentration of Sotalol can be increased when it is combined with Triflupromazine.]
[A03AA05, trimebutine, Sotalol may increase the arrhythmogenic activities of Trimebutine.]
[S01ED04, metipranolol, Sotalol may increase the arrhythmogenic activities of Metipranolol.]
[R06AD01, trimeprazine, The serum concentration of Sotalol can be increased when it is combined with Alimemazine.]
[N03AC02, trimethadione, Trimethadione may increase the arrhythmogenic activities of Sotalol.]
[C02BA01, trimethaphan, Sotalol may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Sotalol.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Sotalol.]
[R06AC04, tripelennamine, The metabolism of Sotalol can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Sotalol.]
[N06AX24, vilazodone, The metabolism of Sotalol can be decreased when combined with Vilazodone.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Sotalol is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, Tubocurarine may increase the bradycardic activities of Sotalol.]
[S01AA05, tyrothricin, Tyrothricin may increase the bradycardic activities of Sotalol.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Vandetanib.]
[L02BX03, abiraterone, The metabolism of Sotalol can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Linagliptin.]
[J05AG05, rilpivirine, The metabolism of Sotalol can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Sotalol.]
[R03AC18, indacaterol, Sotalol may decrease the bronchodilatory activities of Indacaterol.]
[C08DA01, verapamil, The risk or severity of adverse effects can be increased when Verapamil is combined with Sotalol.]
[N06AX09, viloxazine, The metabolism of Sotalol can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Sotalol can be decreased when combined with Vinblastine.]
[C04AX07, vincamine, Sotalol may increase the hypotensive activities of Vincamine.]
[S01AA13, fusidic acid, The metabolism of Sotalol can be decreased when combined with Fusidic acid.]
[N01AX15, xenon, Xenon may increase the cardiodepressant activities of Sotalol.]
[C03BA10, xipamide, Sotalol may increase the hypotensive activities of Xipamide.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Sotalol.]
[N05AF05, zuclopenthixol, The metabolism of Sotalol can be decreased when combined with Zuclopenthixol.]
[L01EC01, vemurafenib, The metabolism of Sotalol can be decreased when combined with Vemurafenib.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Sotalol.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Sotalol.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Ziprasidone.]
[G03AC10, drospirenone, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Drospirenone.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the antihypertensive activities of Sotalol.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Sotalol.]
[G04BD07, tolterodine, The metabolism of Sotalol can be decreased when combined with Tolterodine.]
[C07AB03, atenolol, Atenolol may increase the arrhythmogenic activities of Sotalol.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Sotalol.]
[S01FA01, atropine, Sotalol may increase the arrhythmogenic activities of Atropine.]
[G04BE10, avanafil, The risk or severity of hypotension can be increased when Avanafil is combined with Sotalol.]
[A08AA11, lorcaserin, The metabolism of Sotalol can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Sotalol can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Sotalol can be decreased when combined with Cobicistat.]
[A02AA05, magnesium silicate, The serum concentration of Sotalol can be decreased when it is combined with Magnesium silicate.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Sotalol.]
[L01EX05, regorafenib, Regorafenib may increase the bradycardic activities of Sotalol.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Sotalol.]
[C01AA01, acetyldigitoxin, Sotalol may increase the arrhythmogenic activities of Acetyldigitoxin.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Sotalol.]
[N04BD02, rasagiline, Rasagiline may increase the orthostatic hypotensive activities of Sotalol.]
[C08CA13, lercanidipine, Sotalol may increase the arrhythmogenic activities of Lercanidipine.]
[N06DA02, donepezil, The metabolism of Sotalol can be decreased when combined with Donepezil.]
[L04AA29, tofacitinib, Sotalol may increase the bradycardic activities of Tofacitinib.]
[G04BD10, darifenacin, The metabolism of Sotalol can be decreased when combined with Darifenacin.]
[N01AA01, ethyl ether, Diethyl ether may increase the cardiodepressant activities of Sotalol.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Sotalol.]
[G04BE03, sildenafil, The metabolism of Sotalol can be decreased when combined with Sildenafil.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Sotalol.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Sotalol.]
[C04AX11, bencyclane, Sotalol may increase the arrhythmogenic activities of Bencyclane.]
[A10BH04, alogliptin, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Sotalol can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sotalol.]
[G03XC05, ospemifene, The metabolism of Sotalol can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, Benorilate may decrease the antihypertensive activities of Sotalol.]
[A10BK02, canagliflozin, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Sotalol.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Sotalol.]
[A06AX06, tegaserod, The metabolism of Sotalol can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Sotalol.]
[A10AE05, insulin detemir, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin detemir.]
[R02AD01, benzocaine, The metabolism of Sotalol can be decreased when combined with Benzocaine.]
[A10BX05, pramlintide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Pramlintide.]
[M01AH01, celecoxib, Celecoxib may decrease the antihypertensive activities of Sotalol.]
[L04AA18, everolimus, The metabolism of Sotalol can be decreased when combined with Everolimus.]
[N04AC01, benztropine, The metabolism of Sotalol can be decreased when combined with Benzatropine.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Sotalol.]
[R02AX03, benzydamine, Benzydamine may decrease the antihypertensive activities of Sotalol.]
[P03AX06, benzyl alcohol, The metabolism of Sotalol can be decreased when combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The metabolism of Sotalol can be decreased when combined with Levomilnacipran.]
[C08EA02, bepridil, Sotalol may increase the arrhythmogenic activities of Bepridil.]
[C02KX05, riociguat, The risk or severity of adverse effects can be increased when Sotalol is combined with Riociguat.]
[A10BJ03, lixisenatide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Lixisenatide.]
[C02KX04, macitentan, Sotalol may increase the hypotensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Sotalol can be decreased when combined with Ibrutinib.]
[N06AX26, vortioxetine, The metabolism of Sotalol can be decreased when combined with Vortioxetine.]
[A10BK01, dapagliflozin, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Dapagliflozin.]
[C01CA27, droxidopa, Sotalol may decrease the bronchodilatory activities of Droxidopa.]
[C07AB04, acebutolol, Sotalol may increase the arrhythmogenic activities of Acebutolol.]
[L04AA32, apremilast, The metabolism of Sotalol can be increased when combined with Apremilast.]
[A16AA06, betaine, Betaine may increase the bradycardic activities of Sotalol.]
[S01ED02, betaxolol, Betaxolol may increase the arrhythmogenic activities of Sotalol.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be decreased when used in combination with Sotalol.]
[A10BJ04, albiglutide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Albiglutide.]
[L04AC11, siltuximab, The metabolism of Sotalol can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, Sotalol may increase the bradycardic activities of Ceritinib.]
[A03BA03, hyoscyamine, Hyoscyamine may increase the arrhythmogenic activities of Sotalol.]
[A10BK03, empagliflozin, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Empagliflozin.]
[R03AC19, olodaterol, Sotalol may decrease the bronchodilatory activities of Olodaterol.]
[A16AX10, eliglustat, The metabolism of Sotalol can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Sotalol can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, The serum concentration of Sotalol can be increased when it is combined with Acepromazine.]
[V04CX03, methacholine, Sotalol may increase the bronchoconstrictory activities of Methacholine.]
[A10BJ05, dulaglutide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Dulaglutide.]
[N04AA02, biperiden, The metabolism of Sotalol can be decreased when combined with Biperiden.]
[L04AX05, pirfenidone, The metabolism of Sotalol can be decreased when combined with Pirfenidone.]
[J05AP09, dasabuvir, The metabolism of Sotalol can be decreased when combined with Dasabuvir.]
[N06AX11, mirtazapine, The metabolism of Sotalol can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Sotalol can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Sotalol.]
[L01XH03, panobinostat, The metabolism of Sotalol can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Sotalol can be decreased when combined with Acetaminophen.]
[C01EB17, ivabradine, Sotalol may increase the bradycardic activities of Ivabradine.]
[J05AP06, asunaprevir, The metabolism of Sotalol can be decreased when combined with Asunaprevir.]
[N05AX16, brexpiprazole, The metabolism of Sotalol can be decreased when combined with Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Sotalol can be decreased when combined with Rolapitant.]
[A06AD03, magnesium peroxide, The serum concentration of Sotalol can be decreased when it is combined with Magnesium peroxide.]
[A10BF01, acarbose, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Acarbose.]
[M02AA25, aceclofenac, Aceclofenac may decrease the antihypertensive activities of Sotalol.]
[M01AB11, acemetacin, Acemetacin may decrease the antihypertensive activities of Sotalol.]
[A10AE06, insulin degludec, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin degludec.]
[N05AB07, acetophenazine, The serum concentration of Sotalol can be increased when it is combined with Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Sotalol can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Sotalol.]
[J02AC05, isavuconazole, The metabolism of Sotalol can be decreased when combined with Isavuconazole.]
[B01AC27, selexipag, Sotalol may increase the hypotensive activities of Selexipag.]
[A10BB31, acetohexamide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Acetohexamide.]
[G04CA01, alfuzosin, Sotalol may increase the orthostatic hypotensive activities of Alfuzosin.]
[M01AE16, alminoprofen, Alminoprofen may decrease the antihypertensive activities of Sotalol.]
[N04BC01, bromocriptine, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Bromocriptine.]
[A02AB03, aluminum phosphate, The serum concentration of Sotalol can be decreased when it is combined with Aluminium phosphate.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sotalol.]
[C08CA01, amlodipine, Amlodipine may increase the arrhythmogenic activities of Sotalol.]
[C03CA02, bumetanide, The risk or severity of adverse effects can be increased when Sotalol is combined with Bumetanide.]
[N01BB01, bupivacaine, The serum concentration of Bupivacaine can be increased when it is combined with Sotalol.]
[C07AA19, bupranolol, Sotalol may increase the arrhythmogenic activities of Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Sotalol can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Sotalol.]
[N05BE01, buspirone, The metabolism of Sotalol can be decreased when combined with Buspirone.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, Sotalol may increase the bradycardic activities of Rivastigmine.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Sotalol.]
[S01GX07, azelastine, The metabolism of Sotalol can be decreased when combined with Azelastine.]
[L01XK03, rucaparib, The metabolism of Sotalol can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Sotalol.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may decrease the antihypertensive activities of Sotalol.]
[R03CC12, bambuterol, Sotalol may decrease the bronchodilatory activities of Bambuterol.]
[R03DA08, bamifylline, The risk or severity of adverse effects can be increased when Sotalol is combined with Bamifylline.]
[N07XX16, deutetrabenazine, The metabolism of Sotalol can be decreased when combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Sotalol.]
[N06BC01, caffeine, The risk or severity of adverse effects can be increased when Sotalol is combined with Caffeine.]
[C09AA07, benazepril, The risk or severity of adverse effects can be increased when Sotalol is combined with Benazepril.]
[A10BX06, benfluorex, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Benfluorex.]
[A12AA04, calcium carbonate, The therapeutic efficacy of Sotalol can be decreased when used in combination with Calcium carbonate.]
[G04BA03, calcium chloride, The therapeutic efficacy of Sotalol can be decreased when used in combination with Calcium chloride.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Sotalol.]
[J05AE09, tipranavir, The metabolism of Sotalol can be decreased when combined with Tipranavir.]
[D11AX03, calcium gluconate, The therapeutic efficacy of Sotalol can be decreased when used in combination with Calcium gluconate.]
[N07XX13, valbenazine, The metabolism of Sotalol can be decreased when combined with Valbenazine.]
[L04AB02, infliximab, The metabolism of Sotalol can be increased when combined with Infliximab.]
[A12AA01, calcium phosphate, The therapeutic efficacy of Sotalol can be decreased when used in combination with Calcium Phosphate.]
[N04BD03, safinamide, Safinamide may increase the orthostatic hypotensive activities of Sotalol.]
[N07AB02, bethanechol, The risk or severity of adverse effects can be increased when Sotalol is combined with Bethanechol.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Sotalol.]
[P03AC02, bioallethrin, Sotalol may increase the arrhythmogenic activities of Bioallethrin.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Sotalol is combined with Acetylcholine.]
[L01XX59, enasidenib, The metabolism of Sotalol can be decreased when combined with Enasidenib.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Sotalol.]
[C07AB07, bisoprolol, The risk or severity of adverse effects can be increased when Bisoprolol is combined with Sotalol.]
[R03AC17, bitolterol, Sotalol may decrease the bronchodilatory activities of Bitolterol.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Sotalol.]
[C07AA17, bopindolol, The metabolism of Sotalol can be decreased when combined with Bopindolol.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Sotalol is combined with Nesiritide.]
[C03DA03, canrenone, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Canrenone.]
[M01AB07, bumadizone, Bumadizone may decrease the antihypertensive activities of Sotalol.]
[J05AX18, letermovir, The metabolism of Sotalol can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Sotalol.]
[C01AA02, acetyldigoxins, Sotalol may increase the arrhythmogenic activities of Acetyldigoxin.]
[A10BJ06, semaglutide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Semaglutide.]
[N01BX04, capsaicin, Capsaicin may increase the bradycardic activities of Sotalol.]
[A10BK04, ertugliflozin, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Ertugliflozin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Sotalol.]
[C09AA01, captopril, The risk or severity of adverse effects can be increased when Sotalol is combined with Captopril.]
[S01EB02, carbachol, The risk or severity of adverse effects can be increased when Sotalol is combined with Carbamoylcholine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Macimorelin.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Sotalol can be decreased when used in combination with Calcium polycarbophil.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Sotalol.]
[C07AG02, carvedilol, Sotalol may increase the arrhythmogenic activities of Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Sotalol.]
[N03AX24, cannabidiol, The metabolism of Sotalol can be decreased when combined with Cannabidiol.]
[L01EC03, encorafenib, The metabolism of Sotalol can be decreased when combined with Encorafenib.]
[C07AB08, celiprolol, Sotalol may increase the arrhythmogenic activities of Celiprolol.]
[H01CC03, elagolix, The metabolism of Sotalol can be decreased when combined with Elagolix.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Ivosidenib.]
[P01BA07, tafenoquine, The metabolism of Sotalol can be decreased when combined with Tafenoquine.]
[N03AX17, stiripentol, The metabolism of Sotalol can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Sotalol can be decreased when combined with Dacomitinib.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Sotalol.]
[A10BB06, carbutamide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Carbutamide.]
[M01AC05, lornoxicam, Lornoxicam may decrease the antihypertensive activities of Sotalol.]
[R03DA02, oxtriphylline, The risk or severity of adverse effects can be increased when Sotalol is combined with Oxtriphylline.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Sotalol.]
[R03BB08, revefenacin, The metabolism of Sotalol can be decreased when combined with Revefenacin.]
[L04AA39, emapalumab, The metabolism of Sotalol can be increased when combined with Emapalumab.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Sotalol.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Sotalol.]
[C01BG07, cifenline, Sotalol may increase the arrhythmogenic activities of Cibenzoline.]
[C09AA08, cilazapril, The risk or severity of adverse effects can be increased when Sotalol is combined with Cilazapril.]
[B01AC23, cilostazol, The metabolism of Sotalol can be decreased when combined with Cilostazol.]
[S01ED05, carteolol, Sotalol may increase the arrhythmogenic activities of Carteolol.]
[P02BX04, triclabendazole, The metabolism of Sotalol can be decreased when combined with Triclabendazole.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Sotalol.]
[N05BA09, clobazam, The metabolism of Sotalol can be decreased when combined with Clobazam.]
[V03AE07, calcium acetate, The therapeutic efficacy of Sotalol can be decreased when used in combination with Calcium acetate.]
[C09CA06, candesartan, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Candesartan.]
[L04AB01, etanercept, The metabolism of Sotalol can be increased when combined with Etanercept.]
[N05AA06, cyamemazine, The serum concentration of Sotalol can be increased when it is combined with Cyamemazine.]
[C03BX03, cicletanine, Sotalol may increase the arrhythmogenic activities of Cicletanine.]
[L01EJ02, fedratinib, The metabolism of Sotalol can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Entrectinib.]
[N07XX11, pitolisant, Sotalol may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Sotalol.]
[N04CX01, istradefylline, The metabolism of Sotalol can be decreased when combined with Istradefylline.]
[C03AA09, cyclothiazide, Sotalol may increase the hypotensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The metabolism of Sotalol can be decreased when combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin pork.]
[N02CC08, lasmiditan, Lasmiditan may increase the bradycardic activities of Sotalol.]
[A16AX16, givosiran, The serum concentration of Sotalol can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Sotalol.]
[R06AB02, dexchlorpheniramine, The metabolism of Sotalol can be decreased when combined with Dexchlorpheniramine.]
[M01AX21, diacetylrhein, The metabolism of Sotalol can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Sotalol.]
[H02CA02, osilodrostat, The metabolism of Sotalol can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Sotalol can be decreased when combined with Amprenavir.]
[N02AA08, dihydrocodeine, The metabolism of Sotalol can be decreased when combined with Dihydrocodeine.]
[N02CC06, eletriptan, The metabolism of Sotalol can be decreased when combined with Eletriptan.]
[M01AH02, rofecoxib, Rofecoxib may decrease the antihypertensive activities of Sotalol.]
[C08CA16, clevidipine, Sotalol may increase the arrhythmogenic activities of Clevidipine.]
[C01BD07, dronedarone, Sotalol may increase the QTc-prolonging activities of Dronedarone.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Sotalol.]
[C02AA06, methoserpidine, Sotalol may increase the hypotensive activities of Methoserpidine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Sotalol is combined with Opicapone.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Sotalol.]
[G04BD09, trospium, The metabolism of Sotalol can be decreased when combined with Trospium.]
[M01AC04, droxicam, Droxicam may decrease the antihypertensive activities of Sotalol.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the antihypertensive activities of Sotalol.]
[C08CA17, levamlodipine, The risk or severity of bradycardia can be increased when Levamlodipine is combined with Sotalol.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Sotalol.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Sotalol.]
[P01BB01, proguanil, The metabolism of Sotalol can be decreased when combined with Proguanil.]
[N02AX07, oliceridine, The metabolism of Sotalol can be decreased when combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Sotalol can be decreased when combined with Chloroquine.]
[C03AA04, chlorothiazide, The risk or severity of adverse effects can be increased when Sotalol is combined with Chlorothiazide.]
[R06AB04, chlorpheniramine, The metabolism of Sotalol can be decreased when combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Sotalol can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Chlorpropamide.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Sotalol.]
[C03BA04, chlorthalidone, The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sotalol.]
[M03BB03, chlorzoxazone, The metabolism of Sotalol can be decreased when combined with Chlorzoxazone.]
[A11CC05, cholecalciferol, The metabolism of Sotalol can be decreased when combined with Cholecalciferol.]
[N02BA07, ethenzamide, Ethenzamide may decrease the antihypertensive activities of Sotalol.]
[N06BX18, vinpocetine, Sotalol may increase the arrhythmogenic activities of Vinpocetine.]
[M01AB08, etodolac, Etodolac may decrease the antihypertensive activities of Sotalol.]
[M02AA06, etofenamate, Etofenamate may decrease the antihypertensive activities of Sotalol.]
[B06AC06, berotralstat, The serum concentration of Sotalol can be increased when it is combined with Berotralstat.]
[M09AA01, hydroquinine, Sotalol may increase the arrhythmogenic activities of Hydroquinine.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Sotalol.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Sotalol is combined with Vericiguat.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Sotalol.]
[M01AE05, fenbufen, Fenbufen may decrease the antihypertensive activities of Sotalol.]
[N06BA10, fenethylline, The risk or severity of adverse effects can be increased when Sotalol is combined with Fenethylline.]
[C01CA19, fenoldopam, The risk or severity of adverse effects can be increased when Sotalol is combined with Fenoldopam.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Sotalol.]
[R03CC15, formoterol, The metabolism of Sotalol can be decreased when combined with Formoterol.]
[A10AF01, insulin, regular, human, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Sotalol.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the cardiodepressant activities of Sotalol.]
[L03AB10, peginterferon alfa-2b, The metabolism of Sotalol can be decreased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, The therapeutic efficacy of Sotalol can be decreased when used in combination with Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Sotalol can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, Sotalol may increase the arrhythmogenic activities of Cinnarizine.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Sotalol.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Sotalol.]
[L01XA01, cisplatin, Cisplatin may increase the bradycardic activities of Sotalol.]
[N06AB04, citalopram, The metabolism of Sotalol can be decreased when combined with Citalopram.]
[C03DA05, finerenone, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Finerenone.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Sotalol is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Mobocertinib.]
[R06AA04, clemastine, The metabolism of Sotalol can be decreased when combined with Clemastine.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the antihypertensive activities of Sotalol.]
[A10BB12, glimepiride, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Glimepiride.]
[A10BB08, gliquidone, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Gliquidone.]
[R03CC13, clenbuterol, Sotalol may decrease the bronchodilatory activities of Clenbuterol.]
[A12AA02, calcium glubionate, The therapeutic efficacy of Sotalol can be decreased when used in combination with Calcium glubionate anhydrous.]
[N06AX25, St. John's wort extract, The metabolism of Sotalol can be decreased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The metabolism of Sotalol can be decreased when combined with Ropeginterferon alfa-2b.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Sotalol.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Sotalol is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Sotalol.]
[N06AA04, clomipramine, The metabolism of Sotalol can be decreased when combined with Clomipramine.]
[S01EA04, clonidine, The risk or severity of bradycardia can be increased when Clonidine is combined with Sotalol.]
[A10BX16, tirzepatide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Tirzepatide.]
[A04AA01, ondansetron, The metabolism of Sotalol can be decreased when combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Sotalol.]
[N05AH02, clozapine, The metabolism of Sotalol can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Sotagliflozin.]
[S02DA02, cocaine, The metabolism of Sotalol can be decreased when combined with Cocaine.]
[C02KB01, metyrosine, Sotalol may increase the hypotensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Sotalol can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the antihypertensive activities of Sotalol.]
[R05DA04, codeine, The metabolism of Sotalol can be decreased when combined with Codeine.]
[M03AC05, hexafluorenium, Hexafluronium may increase the bradycardic activities of Sotalol.]
[C01BA13, hydroquinidine, Sotalol may increase the arrhythmogenic activities of Hydroquinidine.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Sotalol.]
[A04AA03, tropisetron, Sotalol may increase the arrhythmogenic activities of Tropisetron.]
[A10BX03, nateglinide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the antihypertensive activities of Sotalol.]
[H01AC03, mecasermin, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin glargine.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Sotalol.]
[R03BA08, ciclesonide, The metabolism of Sotalol can be decreased when combined with Ciclesonide.]
[B01AC10, indobufen, Indobufen may decrease the antihypertensive activities of Sotalol.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Sotalol.]
[M01AH03, valdecoxib, Valdecoxib may decrease the antihypertensive activities of Sotalol.]
[H01AX01, pegvisomant, Pegvisomant may increase the bradycardic activities of Sotalol.]
[C01AA06, lanatoside C, Sotalol may increase the bradycardic activities of Lanatoside C.]
[A03AX10, isometheptene, The therapeutic efficacy of Isometheptene can be decreased when used in combination with Sotalol.]
[N02CC05, almotriptan, The metabolism of Sotalol can be decreased when combined with Almotriptan.]
[M01AH04, parecoxib, Parecoxib may decrease the antihypertensive activities of Sotalol.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Sotalol.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Bemiparin.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Sotalol.]
[M01AA06, kebuzone, Kebuzone may decrease the antihypertensive activities of Sotalol.]
[L01EA01, imatinib, The serum concentration of Sotalol can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Sotalol.]
[C08CA09, lacidipine, Sotalol may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, Sotalol may increase the arrhythmogenic activities of Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Sotalol.]
[N07BC04, lofexidine, The metabolism of Sotalol can be decreased when combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Sotalol.]
[M01AB09, lonazolac, Lonazolac may decrease the antihypertensive activities of Sotalol.]
[M02AA31, loxoprofen, Loxoprofen may decrease the antihypertensive activities of Sotalol.]
[C09AA03, lisinopril, The risk or severity of adverse effects can be increased when Sotalol is combined with Lisinopril.]
[A06AD01, magnesium carbonate, The serum concentration of Sotalol can be decreased when it is combined with Magnesium carbonate.]
[C08CA11, manidipine, Sotalol may increase the arrhythmogenic activities of Manidipine.]
[C07AA14, mepindolol, The metabolism of Sotalol can be decreased when combined with Mepindolol.]
[R06AD07, mequitazine, The metabolism of Sotalol can be decreased when combined with Mequitazine.]
[C01EB10, adenosine, Sotalol may increase the arrhythmogenic activities of Adenosine.]
[C04AX01, cyclandelate, Sotalol may increase the arrhythmogenic activities of Cyclandelate.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Sotalol can be decreased when used in combination with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Sotalol.]
[C03DA04, eplerenone, The risk or severity of adverse effects can be increased when Sotalol is combined with Eplerenone.]
[N05AD03, metylperon, Sotalol may increase the arrhythmogenic activities of Melperone.]
[C03AA07, cyclopenthiazide, Sotalol may increase the hypotensive activities of Cyclopenthiazide.]
[A10BF02, miglitol, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Miglitol.]
[N06AX07, minaprine, The metabolism of Sotalol can be decreased when combined with Minaprine.]
[S01XA18, cyclosporine, The metabolism of Sotalol can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, The metabolism of Sotalol can be decreased when combined with Moclobemide.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Sotalol.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Sotalol.]
[M02AA02, mofebutazone, Mofebutazone may decrease the antihypertensive activities of Sotalol.]
[M01AX22, morniflumate, Morniflumate may decrease the antihypertensive activities of Sotalol.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Sotalol is combined with Conivaptan.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be decreased when used in combination with Sotalol.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Sotalol.]
[M01AH05, etoricoxib, Etoricoxib may decrease the antihypertensive activities of Sotalol.]
[M03CA01, dantrolene, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Dantrolene.]
[C02CC04, debrisoquin, The metabolism of Sotalol can be decreased when combined with Debrisoquine.]
[A04AD11, nabilone, The risk or severity of adverse effects can be increased when Nabilone is combined with Sotalol.]
[M01AX01, nabumetone, Nabumetone may decrease the antihypertensive activities of Sotalol.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Sotalol.]
[C07AB12, nebivolol, Sotalol may increase the arrhythmogenic activities of Nebivolol.]
[N06AX06, nefazodone, The metabolism of Sotalol can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Sotalol.]
[C01CA23, theodrenaline, The risk or severity of adverse effects can be increased when Sotalol is combined with Theodrenaline.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Sotalol.]
[N06AB10, escitalopram, The serum concentration of Sotalol can be increased when it is combined with Escitalopram.]
[G04BD08, solifenacin, The metabolism of Sotalol can be decreased when combined with Solifenacin.]
[A07EC03, olsalazine, Olsalazine may decrease the antihypertensive activities of Sotalol.]
[N06AA01, desipramine, The metabolism of Sotalol can be decreased when combined with Desipramine.]
[C01AA07, deslanoside, Sotalol may increase the arrhythmogenic activities of Deslanoside.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Sotalol is combined with Aliskiren.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Sotalol.]
[M01AE12, oxaprozin, Oxaprozin may decrease the antihypertensive activities of Sotalol.]
[G04BD04, oxybutynin, The metabolism of Sotalol can be decreased when combined with Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Sotalol can be decreased when combined with Dexfenfluramine.]
[L04AB04, adalimumab, The metabolism of Sotalol can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Sotalol can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Sotalol can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The metabolism of Sotalol can be decreased when combined with Dextromethorphan.]
[N06AB05, paroxetine, The metabolism of Sotalol can be decreased when combined with Paroxetine.]
[C04AD01, pentifylline, The risk or severity of adverse effects can be increased when Sotalol is combined with Pentifylline.]
[V03AH01, diazoxide, The risk or severity of adverse effects can be increased when Sotalol is combined with Diazoxide.]
[S02DA04, dibucaine, Cinchocaine may increase the bradycardic activities of Sotalol.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Sotalol is combined with Diclofenamide.]
[S01BC03, diclofenac, Diclofenac may decrease the antihypertensive activities of Sotalol.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Sotalol.]
[C02DG01, pinacidil, Sotalol may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, Sotalol may increase the arrhythmogenic activities of Pinaverium.]
[A10BG03, pioglitazone, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Pioglitazone.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Sotalol is combined with Pipamperone.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Sotalol.]
[R03CC07, pirbuterol, Sotalol may decrease the bronchodilatory activities of Pirbuterol.]
[P02CB02, diethylcarbamazine, Diethylcarbamazine may increase the bradycardic activities of Sotalol.]
[A08AA03, diethylpropion, The therapeutic efficacy of Sotalol can be decreased when used in combination with Diethylpropion.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Sotalol.]
[N02BA11, diflunisal, Diflunisal may decrease the antihypertensive activities of Sotalol.]
[C01AA04, digitoxin, Sotalol may increase the arrhythmogenic activities of Digitoxin.]
[C01AA05, digoxin, Sotalol may increase the arrhythmogenic activities of Digoxin.]
[C02DB01, dihydralazine, Sotalol may increase the hypotensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Sotalol may increase the vasoconstricting activities of Dihydroergocristine.]
[N02CA01, dihydroergotamine, Sotalol may increase the vasoconstricting activities of Dihydroergotamine.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Sotalol.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Sotalol.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Sotalol.]
[C08DB01, diltiazem, Diltiazem may increase the arrhythmogenic activities of Sotalol.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Sotalol.]
[R03CC08, procaterol, Sotalol may decrease the bronchodilatory activities of Procaterol.]
[M02AX03, dimethyl sulfoxide, The metabolism of Sotalol can be decreased when combined with Dimethyl sulfoxide.]
[N06BC02, propentofylline, The risk or severity of adverse effects can be increased when Sotalol is combined with Propentofylline.]
[N02BB04, propyphenazone, Propyphenazone may decrease the antihypertensive activities of Sotalol.]
[M01AB14, proglumetacin, Proglumetacin may decrease the antihypertensive activities of Sotalol.]
[R03DA03, proxyphylline, The risk or severity of adverse effects can be increased when Sotalol is combined with Proxyphylline.]
[R06AA02, diphenhydramine, The metabolism of Sotalol can be decreased when combined with Diphenhydramine.]
[C09AA06, quinapril, The risk or severity of adverse effects can be increased when Sotalol is combined with Quinapril.]
[B01AC07, dipyridamole, Dipyridamole may increase the bradycardic activities of Sotalol.]
[A03FA02, cisapride, The metabolism of Sotalol can be decreased when combined with Cisapride.]
[C09AA05, ramipril, The risk or severity of adverse effects can be increased when Ramipril is combined with Sotalol.]
[N05AL04, remoxipride, The metabolism of Sotalol can be decreased when combined with Remoxipride.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Sotalol.]
[C01BA03, disopyramide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Disopyramide.]
[N07AA03, distigmine, Distigmine may increase the bradycardic activities of Sotalol.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Sotalol.]
[S02AA12, rifamycin SV, The metabolism of Sotalol can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Sotalol can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The metabolism of Sotalol can be increased when combined with Rifaximin.]
[N05AX08, risperidone, Sotalol may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Sotalol.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Sotalol.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Sotalol.]
[L01EX01, sunitinib, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Sunitinib.]
[C03XA01, tolvaptan, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Tolvaptan.]
[L01XG01, bortezomib, The metabolism of Sotalol can be decreased when combined with Bortezomib.]
[G04BE08, tadalafil, Sotalol may increase the hypotensive activities of Tadalafil.]
[S01BC05, ketorolac, Ketorolac may decrease the antihypertensive activities of Sotalol.]
[C02KX02, ambrisentan, Sotalol may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Sotalol can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may decrease the antihypertensive activities of Sotalol.]
[R03AC12, salmeterol, Sotalol may decrease the bronchodilatory activities of Salmeterol.]
[C01CA07, dobutamine, Sotalol may decrease the bronchodilatory activities of Dobutamine.]
[A03FA03, domperidone, The metabolism of Sotalol can be decreased when combined with Domperidone.]
[N06AA16, dothiepin, The metabolism of Sotalol can be decreased when combined with Dosulepin.]
[N06AA12, doxepin, The metabolism of Sotalol can be decreased when combined with Doxepin.]
[L01DB01, doxorubicin, The metabolism of Sotalol can be decreased when combined with Doxorubicin.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Sotalol.]
[N06AB06, sertraline, The metabolism of Sotalol can be decreased when combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Sotalol.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Sotalol.]
[A08AA10, sibutramine, The serum concentration of Sotalol can be increased when it is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Sotalol can be decreased when combined with Simvastatin.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Sotalol.]
[C09AA11, spirapril, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Spirapril.]
[R03DA01, dyphylline, The risk or severity of adverse effects can be increased when Sotalol is combined with Dyphylline.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Sultopride is combined with Sotalol.]
[V04CX07, edrophonium, Edrophonium may increase the bradycardic activities of Sotalol.]
[C07AB13, talinolol, Sotalol may increase the arrhythmogenic activities of Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Temafloxacin.]
[M01AC02, tenoxicam, Tenoxicam may decrease the antihypertensive activities of Sotalol.]
[G04CA03, terazosin, Sotalol may increase the orthostatic hypotensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Sotalol can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, Sotalol may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, Sotalol may increase the arrhythmogenic activities of Tertatolol.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Sotalol.]
[C09AA02, enalapril, The risk or severity of adverse effects can be increased when Sotalol is combined with Enalapril.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the antihypertensive activities of Sotalol.]
[N06AG03, toloxatone, Toloxatone may increase the orthostatic hypotensive activities of Sotalol.]
[N06BA09, atomoxetine, The metabolism of Sotalol can be decreased when combined with Atomoxetine.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Toremifene.]
[C03CA04, torsemide, The risk or severity of adverse effects can be increased when Torasemide is combined with Sotalol.]
[C09AA10, trandolapril, The risk or severity of adverse effects can be increased when Sotalol is combined with Trandolapril.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Sotalol.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Sotalol.]
[N01AB04, enflurane, Enflurane may increase the cardiodepressant activities of Sotalol.]
[C02CA06, urapidil, Sotalol may increase the orthostatic hypotensive activities of Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Sotalol.]
[L01CA04, vinorelbine, The metabolism of Sotalol can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Sotalol.]
[S01GX10, epinastine, The metabolism of Sotalol can be decreased when combined with Epinastine.]
[N06AX16, venlafaxine, The metabolism of Sotalol can be decreased when combined with Venlafaxine.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Sotalol.]
[S01GA03, xylometazoline, Sotalol may increase the arrhythmogenic activities of Xylometazoline.]
[C08CA12, mepirodipine, Sotalol may increase the arrhythmogenic activities of Barnidipine.]
[S01EA01, epinephrine, Sotalol may decrease the bronchodilatory activities of Epinephrine.]
[C09AA15, zofenopril, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Zofenopril.]
[N05CF02, zolpidem, The metabolism of Sotalol can be decreased when combined with Zolpidem.]
[M01AB04, zomepirac, Zomepirac may decrease the antihypertensive activities of Sotalol.]
[N03AX15, zonisamide, Sotalol may increase the arrhythmogenic activities of Zonisamide.]
[A10AB06, insulin glulisine, human, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin glulisine.]
[C02AC02, guanfacine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Sotalol.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Sotalol is combined with Iloprost.]
[C01BG01, moricizine, Sotalol may increase the arrhythmogenic activities of Moricizine.]
[G02AB03, ergonovine, The therapeutic efficacy of Ergometrine can be decreased when used in combination with Sotalol.]
[C04AE01, ergoloid mesylates, USP, Sotalol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N02CA02, ergotamine, Sotalol may increase the vasoconstricting activities of Ergotamine.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Sotalol.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Sotalol.]
[H05BX01, cinacalcet, The metabolism of Sotalol can be decreased when combined with Cinacalcet.]
[J04AK02, ethambutol, The metabolism of Sotalol can be decreased when combined with Ethambutol.]
[C10AA04, fluvastatin, The metabolism of Sotalol can be decreased when combined with Fluvastatin.]
[C01CA15, gepefrine, The therapeutic efficacy of Sotalol can be decreased when used in combination with Gepefrine.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Sotalol is combined with Amifostine.]
[C01BD05, ibutilide, Ibutilide may increase the arrhythmogenic activities of Sotalol.]
[N04AA05, profenamine, Profenamine may increase the bradycardic activities of Sotalol.]
[N03AD01, ethosuximide, Sotalol may increase the arrhythmogenic activities of Ethosuximide.]
[M01AC06, meloxicam, Meloxicam may decrease the antihypertensive activities of Sotalol.]
[S01XA06, ethylmorphine, The metabolism of Sotalol can be decreased when combined with Ethylmorphine.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Sotalol.]
[N01AX07, etomidate, The therapeutic efficacy of Etomidate can be decreased when used in combination with Sotalol.]
[N05AE03, sertindole, The metabolism of Sotalol can be decreased when combined with Sertindole.]
[C01BA05, ajmaline, Sotalol may increase the arrhythmogenic activities of Ajmaline.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Sotalol.]
[A02BA04, nizatidine, Nizatidine may increase the bradycardic activities of Sotalol.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Sotalol.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Sotalol.]
[R06AX12, terfenadine, The metabolism of Sotalol can be decreased when combined with Terfenadine.]
[N06AX12, bupropion, The metabolism of Sotalol can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Sotalol can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, Sotalol may increase the arrhythmogenic activities of Tocainide.]
[C01BC08, encainide, Sotalol may increase the arrhythmogenic activities of Encainide.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Sotalol.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Sotalol.]
[C08CA02, felodipine, Sotalol may increase the arrhythmogenic activities of Felodipine.]
[C08EA01, fendiline, Sotalol may increase the arrhythmogenic activities of Fendiline.]
[N03AX26, fenfluramine, The metabolism of Sotalol can be decreased when combined with Fenfluramine.]
[M01AE04, fenoprofen, Fenoprofen may decrease the antihypertensive activities of Sotalol.]
[R03CC04, fenoterol, Sotalol may decrease the bronchodilatory activities of Fenoterol.]
[N02AB03, fentanyl, Sotalol may increase the bradycardic activities of Fentanyl.]
[R03CC02, albuterol, Sotalol may decrease the bronchodilatory activities of Salbutamol.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Sotalol is combined with Clofarabine.]
[N07AX03, cevimeline, The metabolism of Sotalol can be decreased when combined with Cevimeline.]
[C01BC04, flecainide, Sotalol may increase the arrhythmogenic activities of Flecainide.]
[N02BG04, floctafenine, The risk or severity of adverse effects can be increased when Sotalol is combined with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Sotalol.]
[N07CA03, flunarizine, Sotalol may increase the arrhythmogenic activities of Flunarizine.]
[V03AZ01, ethanol, Ethanol may increase the hypotensive activities of Sotalol.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Sotalol.]
[N06AB03, fluoxetine, The serum concentration of Sotalol can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Flupentixol.]
[N05AB02, fluphenazine, The metabolism of Sotalol can be decreased when combined with Fluphenazine.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the antihypertensive activities of Sotalol.]
[N05AG01, fluspirilene, Sotalol may increase the arrhythmogenic activities of Fluspirilene.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Sotalol.]
[G01AX06, furazolidone, Furazolidone may increase the orthostatic hypotensive activities of Sotalol.]
[J05AE10, darunavir, The metabolism of Sotalol can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The risk or severity of adverse effects can be increased when Sotalol is combined with Furosemide.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Sotalol.]
[N06DA04, galantamine, The metabolism of Sotalol can be decreased when combined with Galantamine.]
[C08DA02, gallopamil, Sotalol may increase the arrhythmogenic activities of Gallopamil.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Sotalol.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Telavancin is combined with Sotalol.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Sotalol.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Sotalol.]
[N04BC06, cabergoline, Sotalol may increase the vasoconstricting activities of Cabergoline.]
[C01CA21, cafedrine, The risk or severity of adverse effects can be increased when Sotalol is combined with Cafedrine.]
[A10BJ02, liraglutide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Liraglutide.]
[A12AA13, calcium citrate, The therapeutic efficacy of Sotalol can be decreased when used in combination with Calcium citrate.]
[A12AA10, calcium gluceptate, The therapeutic efficacy of Sotalol can be decreased when used in combination with Calcium glucoheptonate.]
[A12AA05, calcium lactate, The therapeutic efficacy of Sotalol can be decreased when used in combination with Calcium lactate.]
[A12AA30, calcium levulinate, The therapeutic efficacy of Sotalol can be decreased when used in combination with Calcium levulinate.]
[N03AD03, methsuximide, Sotalol may increase the arrhythmogenic activities of Methsuximide.]
[N01AH02, alfentanil, Sotalol may increase the bradycardic activities of Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Sotalol.]
[A10BB01, glyburide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Glyburide.]
[A10BB09, gliclazide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Glipizide.]
[H04AA01, glucagon, The therapeutic efficacy of Sotalol can be decreased when used in combination with Glucagon.]
[N05CM18, dexmedetomidine, The metabolism of Sotalol can be decreased when combined with Dexmedetomidine.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Sotalol is combined with Nitroglycerin.]
[C01BD04, dofetilide, Dofetilide may increase the arrhythmogenic activities of Sotalol.]
[C02CA04, doxazosin, The metabolism of Sotalol can be decreased when combined with Doxazosin.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Sotalol.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Sotalol.]
[C07AB09, esmolol, Esmolol may increase the arrhythmogenic activities of Sotalol.]
[C09AA09, fosinopril, The risk or severity of adverse effects can be increased when Sotalol is combined with Fosinopril.]
[S01EX01, guanethidine, Guanethidine may increase the hypotensive activities of Sotalol.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Sotalol.]
[P01BX01, halofantrine, The metabolism of Sotalol can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Sotalol is combined with Halothane.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Sotalol.]
[N05AH04, quetiapine, The metabolism of Sotalol can be decreased when combined with Quetiapine.]
[A10AD05, insulin aspart, human, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin aspart.]
[C09CA01, losartan, Sotalol may increase the arrhythmogenic activities of Losartan.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Heparin.]
[A07EC02, mesalamine, Mesalazine may decrease the antihypertensive activities of Sotalol.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Sotalol.]
[R03CC05, hexoprenaline, Sotalol may decrease the bronchodilatory activities of Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Sotalol can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, Sotalol may increase the arrhythmogenic activities of Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may decrease the antihypertensive activities of Sotalol.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Sotalol.]
[C09AA04, perindopril, The risk or severity of adverse effects can be increased when Sotalol is combined with Perindopril.]
[C02DB02, hydralazine, The risk or severity of adverse effects can be increased when Sotalol is combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Sotalol.]
[R05DA03, hydrocodone, The metabolism of Sotalol can be decreased when combined with Hydrocodone.]
[C03AA02, hydroflumethiazide, The risk or severity of adverse effects can be increased when Sotalol is combined with Hydroflumethiazide.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Sotalol.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Sotalol.]
[A12BA02, potassium citrate, Potassium citrate may increase the hyperkalemic activities of Sotalol.]
[G04BD06, propiverine, Sotalol may increase the orthostatic hypotensive activities of Propiverine.]
[P01BA02, hydroxychloroquine, The metabolism of Sotalol can be decreased when combined with Hydroxychloroquine.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Hydroxyzine.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Sotalol.]
[R02AX02, ibuprofen, Ibuprofen may decrease the antihypertensive activities of Sotalol.]
[L01DB06, idarubicin, The metabolism of Sotalol can be decreased when combined with Idarubicin.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sotalol is combined with Sufentanil.]
[N06AA02, imipramine, The metabolism of Sotalol can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Sotalol is combined with Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Sotalol.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Sotalol.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Sotalol.]
[S01BC01, indomethacin, Indomethacin may decrease the antihypertensive activities of Sotalol.]
[C02CA02, indoramin, Sotalol may increase the orthostatic hypotensive activities of Indoramin.]
[N06AX17, milnacipran, The serum concentration of Sotalol can be increased when it is combined with Milnacipran.]
[S01XA28, varenicline, The risk or severity of adverse effects can be increased when Sotalol is combined with Varenicline.]
[A10BH01, sitagliptin, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Sitagliptin.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Sotalol.]
[A10BH02, vildagliptin, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Vildagliptin.]
[C10AA06, cerivastatin, The metabolism of Sotalol can be decreased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Sotalol.]
[C07AA01, alprenolol, Sotalol may increase the arrhythmogenic activities of Alprenolol.]
[V03AB01, ipecac, The metabolism of Sotalol can be decreased when combined with Ipecac.]
[N06AF05, iproniazid, The metabolism of Sotalol can be decreased when combined with Iproniazid.]
[N05AA07, chlorproethazine, The serum concentration of Sotalol can be increased when it is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the orthostatic hypotensive activities of Sotalol.]
[R03CC06, isoetharine, Sotalol may decrease the bronchodilatory activities of Isoetharine.]
[C09AA16, imidapril, The risk or severity of adverse effects can be increased when Sotalol is combined with Imidapril.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Sotalol.]
[S01EB07, isoflurophate, Isoflurophate may increase the bradycardic activities of Sotalol.]
[N04BX02, entacapone, The metabolism of Sotalol can be decreased when combined with Entacapone.]
[R03CB01, isoproterenol, Sotalol may decrease the bronchodilatory activities of Isoprenaline.]
[A10BJ01, exenatide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Exenatide.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Sotalol is combined with Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Sotalol is combined with Isosorbide dinitrate.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Sotalol.]
[N06AX18, reboxetine, The metabolism of Sotalol can be decreased when combined with Reboxetine.]
[A02AB01, aluminum hydroxide, The serum concentration of Sotalol can be decreased when it is combined with Aluminum hydroxide.]
[L04AC07, tocilizumab, The metabolism of Sotalol can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may increase the bradycardic activities of Sotalol.]
[C02KD01, ketanserin, Sotalol may increase the hypotensive activities of Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Sotalol can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The metabolism of Sotalol can be decreased when combined with Olanzapine.]
[M02AA10, ketoprofen, Ketoprofen may decrease the antihypertensive activities of Sotalol.]
[L04AA24, abatacept, The metabolism of Sotalol can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Sotalol.]
[C01CA22, arbutamine, Sotalol may decrease the bronchodilatory activities of Arbutamine.]
[N04BC09, rotigotine, The metabolism of Sotalol can be decreased when combined with Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Sotalol.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the antihypertensive activities of Sotalol.]
[C07AG01, labetalol, The metabolism of Sotalol can be decreased when combined with Labetalol.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Sotalol.]
[C02AA05, deserpidine, Deserpidine may increase the hypotensive activities of Sotalol.]
[N07AA30, ambenonium, Ambenonium may increase the bradycardic activities of Sotalol.]
[N03AX18, lacosamide, Sotalol may increase the bradycardic activities of Lacosamide.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Sotalol is combined with Etacrynic acid.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Sotalol is combined with Levodopa.]
[S02DA01, lidocaine, The serum concentration of Lidocaine can be increased when it is combined with Sotalol.]
[C08EX01, lidoflazine, Sotalol may increase the arrhythmogenic activities of Lidoflazine.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Sotalol is combined with Amiloride.]
[N02CA07, lisuride, The metabolism of Sotalol can be decreased when combined with Lisuride.]
[A07DA03, loperamide, Sotalol may increase the arrhythmogenic activities of Loperamide.]
[A12AA11, calcium pangamate, The therapeutic efficacy of Sotalol can be decreased when used in combination with Calcium pangamate.]
[C10AA02, lovastatin, The metabolism of Sotalol can be decreased when combined with Lovastatin.]
[L01EG01, temsirolimus, The metabolism of Sotalol can be decreased when combined with Temsirolimus.]
[G04BX01, magnesium hydroxide, The serum concentration of Sotalol can be decreased when it is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The serum concentration of Sotalol can be decreased when it is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, Sotalol may increase the arrhythmogenic activities of Magnesium sulfate.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Nilotinib.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Sotalol is combined with Mannitol.]
[N06AA21, maprotiline, The metabolism of Sotalol can be decreased when combined with Maprotiline.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Sotalol is combined with Mecamylamine.]
[L01AA05, mechlorethamine, Mechlorethamine may increase the bradycardic activities of Sotalol.]
[R06AE05, meclizine, The metabolism of Sotalol can be decreased when combined with Meclizine.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the antihypertensive activities of Sotalol.]
[C01AA08, medigoxin, Sotalol may increase the arrhythmogenic activities of Metildigoxin.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be decreased when Mefloquine is combined with Sotalol.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Dalteparin.]
[N06DX01, memantine, Memantine may increase the bradycardic activities of Sotalol.]
[C01CA11, mephentermine, The therapeutic efficacy of Sotalol can be decreased when used in combination with Mephentermine.]
[N03AB04, mephenytoin, The metabolism of Sotalol can be decreased when combined with Mephenytoin.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Sotalol.]
[N01BB03, mepivacaine, The serum concentration of Mepivacaine can be increased when it is combined with Sotalol.]
[N05AC03, mesoridazine, The metabolism of Sotalol can be decreased when combined with Mesoridazine.]
[N05AX13, paliperidone, The metabolism of Sotalol can be decreased when combined with Paliperidone.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be decreased when used in combination with Sotalol.]
[A10BA02, metformin, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Metformin.]
[A04AA04, dolasetron, The metabolism of Sotalol can be decreased when combined with Dolasetron.]
[H01CB03, lanreotide, Sotalol may increase the bradycardic activities of Lanreotide.]
[N07BC02, methadone, The metabolism of Sotalol can be decreased when combined with Methadone.]
[N06BA03, methamphetamine, The therapeutic efficacy of Sotalol can be decreased when used in combination with Metamfetamine.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Sotalol is combined with Methazolamide.]
[G02CB05, metergoline, Sotalol may increase the vasoconstricting activities of Metergoline.]
[H03BB02, methimazole, The excretion of Sotalol can be decreased when combined with Methimazole.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Sotalol.]
[N02BG08, ziconotide, Sotalol may increase the arrhythmogenic activities of Ziconotide.]
[N05AA02, methotrimeprazine, The metabolism of Sotalol can be decreased when combined with Methotrimeprazine.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be decreased when used in combination with Sotalol.]
[N02BG09, methoxyflurane, The metabolism of Sotalol can be decreased when combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sotalol.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be decreased when used in combination with Sotalol.]
[V04CG05, methylene blue, The metabolism of Sotalol can be decreased when combined with Methylene blue.]
[G02AB01, methylergonovine, Sotalol may increase the vasoconstricting activities of Methylergometrine.]
[R03DA05, aminophylline, The risk or severity of adverse effects can be increased when Sotalol is combined with Aminophylline.]
[N02CA04, methysergide, Sotalol may increase the vasoconstricting activities of Methysergide.]
[A03FA01, metoclopramide, The metabolism of Sotalol can be decreased when combined with Metoclopramide.]
[C03BA08, metolazone, The risk or severity of adverse effects can be increased when Sotalol is combined with Metolazone.]
[C07AB02, metoprolol, Metoprolol may increase the arrhythmogenic activities of Sotalol.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Sotalol.]
[C01BB02, mexiletine, Mexiletine may increase the arrhythmogenic activities of Sotalol.]
[N06AX03, mianserin, The metabolism of Sotalol can be decreased when combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Sotalol can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, Aminophenazone may decrease the antihypertensive activities of Sotalol.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Parnaparin.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be decreased when used in combination with Sotalol.]
[G03XB01, mifepristone, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Mifepristone.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Tinzaparin.]
[C09CA03, valsartan, The risk or severity of adverse effects can be increased when Valsartan is combined with Sotalol.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Minoxidil is combined with Sotalol.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Sotalol can be decreased when used in combination with Lisdexamfetamine.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Sotalol.]
[C01BD01, amiodarone, The therapeutic efficacy of Sotalol can be increased when used in combination with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Sotalol can be decreased when combined with Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Sotalol.]
[A04AA05, palonosetron, The metabolism of Sotalol can be decreased when combined with Palonosetron.]
[L04AB05, certolizumab pegol, The metabolism of Sotalol can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Ammonium chloride.]
[L01EX03, pazopanib, The metabolism of Sotalol can be decreased when combined with Pazopanib.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Sotalol.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be decreased when Amodiaquine is combined with Sotalol.]
[G04CA04, silodosin, Sotalol may increase the orthostatic hypotensive activities of Silodosin.]
[N06AA17, amoxapine, The metabolism of Sotalol can be decreased when combined with Amoxapine.]
[C07AA12, nadolol, Sotalol may increase the arrhythmogenic activities of Nadolol.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Sotalol.]
[L04AC03, anakinra, The metabolism of Sotalol can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The therapeutic efficacy of Naphazoline can be decreased when used in combination with Sotalol.]
[N06BA01, amphetamine, The therapeutic efficacy of Sotalol can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, Naproxen may decrease the antihypertensive activities of Sotalol.]
[A10BG01, troglitazone, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Sotalol is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Sotalol.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Sotalol is combined with Remifentanil.]
[A10BX02, repaglinide, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Repaglinide.]
[C01CX08, levosimendan, Sotalol may increase the arrhythmogenic activities of Levosimendan.]
[S01EB06, neostigmine, Neostigmine may increase the bradycardic activities of Sotalol.]
[N05AX14, iloperidone, The metabolism of Sotalol can be decreased when combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Sotalol is combined with Amphotericin B.]
[N06AX23, desvenlafaxine, The metabolism of Sotalol can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, The risk or severity of adverse effects can be increased when Sotalol is combined with Telmisartan.]
[C10AD02, niacin, The metabolism of Sotalol can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the orthostatic hypotensive activities of Sotalol.]
[C08CA04, nicardipine, Sotalol may increase the arrhythmogenic activities of Nicardipine.]
[C04AE02, nicergoline, The metabolism of Sotalol can be decreased when combined with Nicergoline.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Sotalol is combined with Nicotine.]
[C08CA05, nifedipine, The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Sotalol.]
[M02AA17, niflumic acid, Niflumic acid may decrease the antihypertensive activities of Sotalol.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Sotalol is combined with Amyl Nitrite.]
[C08CA06, nimodipine, Nimodipine may increase the arrhythmogenic activities of Sotalol.]
[C08CA07, nisoldipine, Nisoldipine may increase the arrhythmogenic activities of Sotalol.]
[C08CA08, nitrendipine, Sotalol may increase the arrhythmogenic activities of Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sotalol.]
[J01XE01, nitrofurantoin, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Nitrofurantoin.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be increased when Pramipexole is combined with Sotalol.]
[C02DD01, nitroprusside, The risk or severity of adverse effects can be increased when Nitroprusside is combined with Sotalol.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the cardiodepressant activities of Sotalol.]
[C01CA03, norepinephrine, Sotalol may decrease the bronchodilatory activities of Norepinephrine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Sotalol.]
[C02KX01, bosentan, Sotalol may increase the hypotensive activities of Bosentan.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Sotalol.]
[G02CA02, nylidrin, Sotalol may increase the arrhythmogenic activities of Nylidrin.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Sotalol.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Sotalol.]
[L04AC04, rilonacept, The metabolism of Sotalol can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Sotalol can be decreased when combined with Omeprazole.]
[N02AA02, opium, The metabolism of Sotalol can be decreased when combined with Opium.]
[R03CB03, metaproterenol, Sotalol may decrease the bronchodilatory activities of Orciprenaline.]
[G04CA02, tamsulosin, The metabolism of Sotalol can be decreased when combined with Tamsulosin.]
[C01AC01, ouabain, Sotalol may increase the bradycardic activities of Ouabain.]
[P02BA02, oxamniquine, The metabolism of Sotalol can be decreased when combined with Oxamniquine.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Sotalol.]
[C07AA02, oxprenolol, Sotalol may increase the arrhythmogenic activities of Oxprenolol.]
[N02AA05, oxycodone, The metabolism of Sotalol can be decreased when combined with Oxycodone.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Sotalol.]
[S01GA04, oxymetazoline, The risk or severity of cardiovascular complications can be increased when Sotalol is combined with Oxymetazoline.]
[N02AA11, oxymorphone, The metabolism of Sotalol can be decreased when combined with Oxymorphone.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the antihypertensive activities of Sotalol.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Sotalol.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Asenapine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Danaparoid.]
[M03AC01, pancuronium, Pancuronium may increase the bradycardic activities of Sotalol.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Sotalol.]
[C02KC01, pargyline, Pargyline may increase the orthostatic hypotensive activities of Sotalol.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Sotalol.]
[G04BD11, fesoterodine, The metabolism of Sotalol can be decreased when combined with Fesoterodine.]
[C07AA23, penbutolol, The metabolism of Sotalol can be decreased when combined with Penbutolol.]
[N05AG03, penfluridol, Sotalol may increase the arrhythmogenic activities of Penfluridol.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Sotalol.]
[C04AD03, pentoxifylline, The risk or severity of adverse effects can be increased when Sotalol is combined with Pentoxifylline.]
[N05AB10, perazine, The serum concentration of Sotalol can be increased when it is combined with Perazine.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Sotalol.]
[C08EX02, perhexiline, Sotalol may increase the arrhythmogenic activities of Perhexiline.]
[N05AB03, perphenazine, The metabolism of Sotalol can be decreased when combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Sotalol can be decreased when combined with Phenacetin.]
[N06AF03, phenelzine, Phenelzine may increase the orthostatic hypotensive activities of Sotalol.]
[A10BA01, phenformin, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Phenformin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Sotalol.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Sotalol.]
[C04AX02, phenoxybenzamine, Sotalol may increase the orthostatic hypotensive activities of Phenoxybenzamine.]
[A08AA01, phentermine, The therapeutic efficacy of Sotalol can be decreased when used in combination with Phentermine.]
[V03AB36, phentolamine, Sotalol may increase the orthostatic hypotensive activities of Phentolamine.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the antihypertensive activities of Sotalol.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Sotalol.]
[R01BA01, phenylpropanolamine, Sotalol may decrease the bronchodilatory activities of Phenylpropanolamine.]
[N03AB02, phenytoin, The metabolism of Sotalol can be decreased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Sotalol can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Sotalol.]
[V03AB19, physostigmine, Physostigmine may increase the bradycardic activities of Sotalol.]
[C08CX01, mibefradil, Sotalol may increase the arrhythmogenic activities of Mibefradil.]
[S01EB01, pilocarpine, The risk or severity of adverse effects can be increased when Sotalol is combined with Pilocarpine.]
[N05AG02, pimozide, The metabolism of Sotalol can be decreased when combined with Pimozide.]
[C07AA03, pindolol, The metabolism of Sotalol can be decreased when combined with Pindolol.]
[J05AE01, saquinavir, The metabolism of Sotalol can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Sotalol can be decreased when combined with Piperazine.]
[N05AC04, pipothiazine, The metabolism of Sotalol can be decreased when combined with Pipotiazine.]
[C09CA02, eprosartan, The risk or severity of adverse effects can be increased when Sotalol is combined with Eprosartan.]
[S01BC06, piroxicam, Piroxicam may decrease the antihypertensive activities of Sotalol.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Grepafloxacin is combined with Sotalol.]
[N02CX01, pizotyline, Sotalol may increase the orthostatic hypotensive activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Sotalol can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The risk or severity of adverse effects can be increased when Sotalol is combined with Irbesartan.]
[A10BG02, rosiglitazone, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Rosiglitazone.]
[L04AC08, canakinumab, The metabolism of Sotalol can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Sotalol may increase the hypotensive activities of Polythiazide.]
[J05AE03, ritonavir, The metabolism of Sotalol can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Saxagliptin.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Sotalol.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Sotalol.]
[A10AD04, insulin lispro, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Insulin lispro.]
[C07AB01, practolol, Sotalol may increase the arrhythmogenic activities of Practolol.]
[C01BA08, prajmaline, Sotalol may increase the arrhythmogenic activities of Prajmaline.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Sotalol.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Antazoline is combined with Sotalol.]
[C01DX02, prenylamine, Sotalol may increase the arrhythmogenic activities of Prenylamine.]
[P01BA03, primaquine, The metabolism of Sotalol can be decreased when combined with Primaquine.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Sotalol.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Sotalol.]
[C01BA02, procainamide, Sotalol may increase the arrhythmogenic activities of Procainamide.]
[S01HA05, procaine, Procaine may increase the bradycardic activities of Sotalol.]
[L01XB01, procarbazine, Procarbazine may increase the orthostatic hypotensive activities of Sotalol.]
[N05AB04, prochlorperazine, The metabolism of Sotalol can be decreased when combined with Prochlorperazine.]
[G03DA04, progesterone, The metabolism of Sotalol can be decreased when combined with Progesterone.]
[N05AA03, promazine, The metabolism of Sotalol can be decreased when combined with Promazine.]
[R06AD02, promethazine, The metabolism of Sotalol can be decreased when combined with Promethazine.]
[C01BC03, propafenone, The risk or severity of adverse effects can be increased when Propafenone is combined with Sotalol.]
[N05AC01, periciazine, The serum concentration of Sotalol can be increased when it is combined with Periciazine.]
[N05CM06, propiomazine, Sotalol may increase the orthostatic hypotensive activities of Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Sotalol is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Sotalol.]
[N02AC04, propoxyphene, The metabolism of Sotalol can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, Sotalol may increase the arrhythmogenic activities of Propranolol.]
[C01AB01, proscillaridin, Sotalol may increase the bradycardic activities of Proscillaridin.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Sotalol is combined with Epoprostenol.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Sotalol.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Sotalol can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The metabolism of Sotalol can be decreased when combined with Aripiprazole.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Sotalol.]
[N07AA02, pyridostigmine, Pyridostigmine may increase the bradycardic activities of Sotalol.]
[R06AC01, pyrilamine, The metabolism of Sotalol can be decreased when combined with Mepyramine.]
[C01BA01, quinidine, Sotalol may increase the arrhythmogenic activities of Quinidine.]
[P01BC01, quinine, The risk or severity of hypoglycemia can be increased when Sotalol is combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Sotalol can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, The risk or severity of hyperkalemia can be increased when Sotalol is combined with Rescinnamine.]
[C02AA02, reserpine, Reserpine may increase the hypotensive activities of Sotalol.]
[J04AB02, rifampin, The metabolism of Sotalol can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Sotalol.]
[G02CA01, ritodrine, Sotalol may decrease the bronchodilatory activities of Ritodrine.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Sotalol.]
[N02BA05, salicylamide, Salicylamide may decrease the antihypertensive activities of Sotalol.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the antihypertensive activities of Sotalol.]
[S01BC08, salicylic acid, Salicylic acid may decrease the antihypertensive activities of Sotalol.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Sotalol.]
[N04BD01, selegiline, The metabolism of Sotalol can be decreased when combined with Selegiline.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Sotalol is combined with Obinutuzumab.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Spironolactone is combined with Sotalol.]
[N05AL01, sulpiride, QT prolonging agents - QT prolonging agents]
[N05AC02, thioridazine, QT prolonging agents - QT prolonging agents]
[L01EX04, vandetanib, QT prolonging agents - QT prolonging agents]
[N06DA02, donepezil, QT prolonging agents - QT prolonging agents]
[S01AE07, moxifloxacin, QT prolonging agents - QT prolonging agents]
[C08EA02, bepridil, QT prolonging agents - QT prolonging agents]
[L01XX27, arsenic trioxide, QT prolonging agents - QT prolonging agents]
[J01MA09, sparfloxacin, QT prolonging agents - QT prolonging agents]
[S01AA26, azithromycin, QT prolonging agents - QT prolonging agents]
[B01AC23, cilostazol, QT prolonging agents - QT prolonging agents]
[J01FA09, clarithromycin, QT prolonging agents - QT prolonging agents]
[S01AE06, gatifloxacin, QT prolonging agents - QT prolonging agents]
[C01BD07, dronedarone, QT prolonging agents - QT prolonging agents]
[L01DB04, aclarubicin, QT prolonging agents - QT prolonging agents]
[P01BA01, chloroquine, QT prolonging agents - QT prolonging agents]
[N05AA01, chlorpromazine, QT prolonging agents - QT prolonging agents]
[N05AF03, chlorprothixene, QT prolonging agents - QT prolonging agents]
[S03AA07, ciprofloxacin, QT prolonging agents - QT prolonging agents]
[N06AB04, citalopram, QT prolonging agents - QT prolonging agents]
[L01EB10, mobocertinib, QT prolonging agents - QT prolonging agents]
[A04AA01, ondansetron, QT prolonging agents - QT prolonging agents]
[S02DA02, cocaine, QT prolonging agents - QT prolonging agents]
[C01BA13, hydroquinidine, QT prolonging agents - QT prolonging agents]
[P01CB01, meglumine antimoniate, QT prolonging agents - QT prolonging agents]
[L01XA03, oxaliplatin, QT prolonging agents - QT prolonging agents]
[A03FA02, cisapride, QT prolonging agents - QT prolonging agents]
[C01BA03, disopyramide, QT prolonging agents - QT prolonging agents]
[A03FA03, domperidone, QT prolonging agents - QT prolonging agents]
[N01AB08, sevoflurane, QT prolonging agents - QT prolonging agents]
[N05AD08, droperidol, QT prolonging agents - QT prolonging agents]
[N05AL02, sultopride, QT prolonging agents - QT prolonging agents]
[G04BD05, terodiline, QT prolonging agents - QT prolonging agents]
[S01AA17, erythromycin, QT prolonging agents - QT prolonging agents]
[C01BD05, ibutilide, QT prolonging agents - QT prolonging agents]
[N05AE03, sertindole, QT prolonging agents - QT prolonging agents]
[R06AX11, astemizole, QT prolonging agents - QT prolonging agents]
[R06AX12, terfenadine, QT prolonging agents - QT prolonging agents]
[C01BC04, flecainide, QT prolonging agents - QT prolonging agents]
[J02AC01, fluconazole, QT prolonging agents - QT prolonging agents]
[C01BD04, dofetilide, QT prolonging agents - QT prolonging agents]
[P01BX01, halofantrine, QT prolonging agents - QT prolonging agents]
[N05AD01, haloperidol, QT prolonging agents - QT prolonging agents]
[P01BA02, hydroxychloroquine, QT prolonging agents - QT prolonging agents]
[H01BA04, terlipressin, QT prolonging agents - QT prolonging agents]
[L01XX35, anagrelide, QT prolonging agents - QT prolonging agents]
[N05AC03, mesoridazine, QT prolonging agents - QT prolonging agents]
[N07BC02, methadone, QT prolonging agents - QT prolonging agents]
[N05AA02, methotrimeprazine, QT prolonging agents - QT prolonging agents]
[C01BD01, amiodarone, QT prolonging agents - QT prolonging agents]
[S01AE05, levofloxacin, QT prolonging agents - QT prolonging agents]
[N05AG02, pimozide, QT prolonging agents - QT prolonging agents]
[J01MA11, grepafloxacin, QT prolonging agents - QT prolonging agents]
[C10AX02, probucol, QT prolonging agents - QT prolonging agents]
[C01BA02, procainamide, QT prolonging agents - QT prolonging agents]
[N01AX10, propofol, QT prolonging agents - QT prolonging agents]
[C01BA01, quinidine, QT prolonging agents - QT prolonging agents]
[J01FA06, roxithromycin, QT prolonging agents - QT prolonging agents]
